🔗 Share this article

Elected officials have issued warnings that the United Kingdom's recent agreements with Donald Trump are "fundamentally unstable." This comes after revelations that a much-touted deal on medicines, which commits to zero tariffs in exchange for the NHS paying more, lacks any detailed agreement beyond vague headline terms outlined by government press releases.

An Agreement in Principle Only

The US-UK pharmaceuticals agreement, described as a "generational" achievement, remains an "broad understanding" without a signed legal text. Critics have noted that the public statements from the UK and US governments frame the deal in sharply different terms. The British version emphasizes securing "duty-free access" as a unique achievement, while the American announcement highlights the expectation for the NHS to pay 25% more for new medications.

"The danger exists that the UK government has promised concessions to raise drug prices in return for nothing more than a pledge from President Trump," commented David Henig, a trade expert. "It is documented he has a record of not keeping promises."

Broader Instability and a Paused Tech Deal

Anxieties have been intensified by Washington's action to pause the high-value digital accord, which was previously called "a huge leap forward" in the bilateral relationship. The US claimed a insufficient movement from the UK on addressing wider trade issues as the reason for the pause.

Furthermore, concessions agreed to for British farmers as part of an initial accord have yet to be formally approved by the US, despite a imminent January deadline. "We have been informed that that the US has not yet signed off the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Behind the scenes, ministers have expressed concerns that the government's agreements with the US are flimsy and unreliable. One minister reportedly said the series of agreements as "resting on shaky ground," while another characterized the situation as the "new normal" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, argued: "The only thing more surprising than the administration's tactics is the UK government's optimistic assumption that his administration is a reliable partner. The NHS is not a bargaining chip."

Government Downplays Risks, Points to Gains

Government figures have sought to reduce the chances of the US reneging on the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been pushing for the agreement, wanting clarity on imports and pricing, making it of tangible value than the paused tech deal.

Officials admit that instability is part and parcel of dealing with the Trump administration. However, they contend that the UK has obtained tangible results for businesses, such as lower steel tariffs compared to other nations. "The fact we have 25% steel tariffs, which is more favorable than the rate for the rest of the world, is not flimsy," one official said.

Yet, problems have arisen in enacting the broader trade deal. Promised reciprocal agricultural allowances have failed to be approved, and the commitment to "eliminate duties on UK metals" has remains unmet, with tariffs staying at 25%.

As negotiations continue, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "very positive" meetings between UK and US officials in Washington.